| Date | Title | Description |
| 10.12.2020 | NBE Therapeutics makes a €1.18 billion exit | |
| 10.12.2020 | NBE Therapeutics makes a €1.18 billion exit | NBE-Therapeutics is a clinical-stage Swiss biotechnology company is focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC platform. Its lead compound NBE-002 is currently in pha... |
| 28.10.2020 | NBE-Therapeutics launches first clinical trials | |
| 28.10.2020 | NBE-Therapeutics launches first clinical trials | NBE-Therapeutics is a Swiss-based company developing best-in-class cancer therapies based on its proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform. The iADC platform creates highly potent, safe and immune-stimulatory... |
| 05.10.2020 | Startups win strong and well-connected board members | |
| 05.10.2020 | Startups win strong and well-connected board members | NBE Therapeutics, Erich Schlick, chairman of the board of Director
NBE-Therapeutics, a biotech company developing best-in-class cancer therapies based on its proprietary, highly differentiated Antibody Drug Conjugate (ADC) platform, announc... |
| 10.09.2020 | NBE-Therapeutics receives USD 25 million upfront payment | Based in Basel, NBE-Therapeutics is focused on developing next-generation, best-in-class ADCs targeting solid tumours as well as haematological malignancies. NBE’s platform improves upon older ADC platforms by delivering highly homogenous, ... |
| 10.09.2020 | NBE-Therapeutics receives USD 25 million upfront payment | |
| 10.08.2020 | An almost complete C-suite for Swiss startups | |
| 10.08.2020 | An almost complete C-suite for Swiss startups | NBE-Therapeutics, Chief Executive Officer
The Swiss-based company is developing best in class cancer therapies based on its proprietary, highly differentiated Antibody Drug Conjugate (ADC) platform. The first-in-human study with lead candid... |
| 13.01.2020 | Swiss Biotech Startup NBE-Therapeutics Closes a USD 22M Series C Financing Round | Swiss Biotech Startup NBE-Therapeutics Closes a USD 22M Series C Financing Round 13.01.2020 14:49, Gianmaria Sbetta linkedIn facebook twitter instagram youtube -->
TOP 100 and Venture Leaders alumn NBE-Therapeutics closes a USD 22M Serie... |
| 10.01.2020 | NBE-Therapeutics closes USD 22 million financing round | NBE-Therapeutics’ best in class iADC platform creates highly potent and safe immune-stimulatory ADCs (Antibody Drug Conjugates) - Antibodies attached to biologically active drugs by chemical linkers. NBE’s ADCs include an anthracycline payl... |
| 10.01.2020 | NBE-Therapeutics closes USD 22 million financing round | |
| 10.01.2020 | 23andMe finds a buyer for its IL-36 bispecific in Almirall; Neurocrine, Idorsia revise epilepsy drug deal | → The first fruits of 23andMe’s efforts to generate new drugs off the insights it gained from a massive amount of genetic data are taking shape, and Almirall is signing up to ripen one of them. The Spanish dermatology drugma... |
| 10.01.2020 | NBE-Therapeutics Completes USD22M Series C Financing Round | NBE-Therapeutics AG, a Basel, Switzerland-based biotech company, closed a USD 22M Series C financing round.
The round was led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all p... |
| 07.11.2019 | SOTIO exercises second target option under existing collaboration with NBE-Therapeutics to develop next-generation antibody-drug conjugates | Basel, Switzerland & Prague, Czech Republic – November 7, 2019 – NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate (ADC) under thei... |
| 07.11.2019 | SOTIO expands collaboration with NBE Therapeutics | |
| 29.10.2019 | Biotech startups strengthen their teams | |
| 03.07.2018 | $20m shot in the arm for NBE Therapeutics | $20m shot in the arm for NBE Therapeutics 03.07.2018 14:15, Robynn Weldon linkedIn facebook twitter instagram youtube -->
Cancer treatment company NBE Therapeutics has received $20 million of investment from Novo Holdings, adding to prev... |
| 28.06.2018 | NOVO Holdings invests CHF 20 million in NBE Therapeutics | |
| 28.06.2018 | As Alexion fields applications for ALXN1210, a rival aims for the crown with head-to-head PhIII; Novo hands NBE €20M | → Alexion $ALXN has filed for a European approval for ALXN1210, one in a series of applications that followed the recent application in the US. Designed to succeed their franchise drug Soliris, the drug has some advantages... |
| 28.06.2018 | ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Novo Holdings has invested CHF 20 million ($20 million) in NBE Therapeutics, doubling the size of the startup’s series B round. NBE will use the money to start testing anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in solid tumor patients.... |
| 28.06.2018 | ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Novo Holdings has invested CHF 20 million ($20 million) in NBE Therapeutics, doubling the size of the startup’s series B round. NBE will use the money to start testing anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in solid tumor patients.... |
| 28.06.2018 | Biopharma Company NBE Therapeutics Raises Further CHF20M in Series B | NBE Therapeutics AG, a Basel, Switzerland-based biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for improved cancer therapy, raised a CHF20m extension of the Series B round.
Together with an earlier CHF2... |
| 14.03.2018 | Gute Aussichten für Basler Startups | |
| 04.12.2017 | NBE Therapeutics welcomes expert in clinical development of oncology drugs to its Board of directors | |
| 10.11.2017 | "An IPO has become a serious alternative” | |
| 28.12.2016 | venturelab Startup Highlights 2016 | venturelab Startup Highlights 2016 28.12.2016 15:00, Tsering Ngorkhangsar linkedIn facebook twitter instagram youtube -->
Es war ein unglaubliches Jahr für unsere venturelab Startups. Sie waren sehr engagiert und haben hart für die Errei... |
| 08.11.2016 | Term Sheet — Tuesday, November 8 | Et cetera
I’m going to take a wild guess that many of you are reading Term Sheet from a long polling line. Here’s a few news items to help you pass the time:
Paid Content What you need to know about growing cyberattacks From ExtraHop
I thou... |
| 06.11.2016 | NBE-Therapeutics Raises CHF20M in Series B Funding | NBE-Therapeutics, a Basel, Switzerland-based biotech company, closed a CHF20M Series B funding.
The round was led by PPF Group with participation from Boehringer Ingelheim Venture Fund, other existing investors and a new private investor. I... |
| 03.11.2016 | NBE Therapeutics Raises CHF 20 Million in Series B Funding | |
| 01.11.2016 | New partner and investor for NBE Therapeutics | |
| 19.01.2016 | Financial support for NBE-Therapeutics’ R&D project | |
| 24.03.2015 | NBE-Therapeutics closes CHF 3.0 Mio series A financing | |
| 28.11.2014 | NBE-Therapeutics obtained CHF 600K SystemsX grant | |
| 11.09.2014 | Four start-ups awarded with the CTI start-up label | |
| 26.02.2014 | NBE-Therapeutics Announces Successful Validation of its Technology | |
| 21.10.2013 | Unternehmer und Investoren über grösste Fehler und ungewöhnliche Wege zum Erfolg | |
| 07.06.2013 | Successful first year for NBE-Therapeutics | |
| 31.07.2012 | Ulf Grawunder starts new Life Science Company | |
